Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Annals of Hematology|February 28, 2021
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trialJames Russell, Angela Collins, Alexis Fowler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II studyPeter Hillmen, John G Gribben, George A Follows, et al.
Nature Genetics|May 5, 2015
Mapping long-range promoter contacts in human cells with high-resolution capture Hi-CBorbala Mifsud, Filipe Tavares-Cadete, Alice N Young, et al.
The Lancet. Oncology|November 9, 2023
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialCarsten U Niemann, Talha Munir, Carol Moreno, et al.
Haematologica|February 11, 2021
Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysisRachel Dobson, Peter Y Du, Lívia Rásó-Barnett, et al.
The Journal of Pathology. Clinical Research|June 28, 2016
The prognosis of <i>MYC</i> translocation positive diffuse large B-cell lymphoma depends on the second hitAlexandra Clipson, Sharon Barrans, Naiyan Zeng, et al.
The Journal of Pathology|December 21, 2019
Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cellWen-Qing Yao, Fangtian Wu, Wenyan Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.
Blood|March 5, 2016
BRAF inhibition in hairy cell leukemia with low-dose vemurafenibSascha Dietrich, Andreas Pircher, Volker Endris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2017
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent LymphomaMartin Dreyling, Armando Santoro, Luigina Mollica, et al.
Pageof 5